RT Journal Article
SR Electronic
T1 Fatal cytokine release syndrome by an aberrant FLIP/STAT3 axis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.04.21256298
DO 10.1101/2021.05.04.21256298
A1 Musiu, Chiara
A1 Caligola, Simone
A1 Fiore, Alessandra
A1 Lamolinara, Alessia
A1 Frusteri, Cristina
A1 Del Pizzo, Francesco Domenico
A1 De Sanctis, Francesco
A1 Canè, Stefania
A1 Adamo, Annalisa
A1 Hofer, Francesca
A1 Barouni, Roza Maria
A1 Grilli, Andrea
A1 Zilio, Serena
A1 Serafini, Paolo
A1 Tacconelli, Evelina
A1 Donadello, Katia
A1 Gottin, Leonardo
A1 Polati, Enrico
A1 Girelli, Domenico
A1 Polidoro, Ildo
A1 Iezzi, Piera Amelia
A1 Angelucci, Domenico
A1 Capece, Andrea
A1 Chen, Ying
A1 Shi, Zheng-Li
A1 Murray, Peter J.
A1 Chilosi, Marco
A1 Amit, Ido
A1 Bicciato, Silvio
A1 Iezzi, Manuela
A1 Bronte, Vincenzo
A1 Ugel, Stefano
YR 2021
UL http://medrxiv.org/content/early/2021/05/04/2021.05.04.21256298.abstract
AB Inflammatory responses rapidly detect pathogen invasion and mount a regulated reaction. However, dysregulated anti-pathogen immune responses can provoke life-threatening inflammatory pathologies collectively known as cytokine release syndrome (CRS), exemplified by key clinical phenotypes unearthed during the SARS-Cov-2 pandemic. The underlying pathophysiology of CRS remains elusive. We found that FLIP, a protein that controls caspase-8 death pathways, was highly expressed in myeloid cells of COVID-19 lungs. FLIP controlled CRS by fueling a STAT3-dependent inflammatory program. Indeed, constitutive expression of a viral FLIP homologue in myeloid cells triggered a STAT3-linked, progressive and fatal inflammatory syndrome in mice, characterized by elevated cytokine output, lymphopenia, lung injury and multiple organ dysfunctions that mimicked human CRS. As STAT3-targeting approaches relieved inflammation, immune disorders, and organ failures in these mice, targeted intervention towards this pathway could suppress the lethal CRS inflammatory state.One sentence summary FLIP-expressing myeloid cells are key drivers of CRS through aberrant overexpression of STAT3 pathway. STAT3-targeting is effective in mitigating CRS like severe COVID-19.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04438629Funding StatementThis work was jointly supported by both S. Ugel grants of the Fondazione Italian Association for Cancer Research (AIRC, MFAG project: 21509) and PRIN program of Italian Ministry of Education, University and Research (MIUR, CUP: B38D19000140006) and V. Bronte grants funded by Fondazione Cariverona (ENACT Project), Fondazione TIM (Immunovid Project), Fondazione AIRC (23788), Cancer Research Institute (Clinic and Laboratory Integration Program, CLIP 2020), European Research Commission (Euronanomed III, Joint Traslational Call_2017, Project RESOLVE) and MIUR (CUP: B38D19000260006).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Review board of Azienda Ospedaliera Universitaria di Verona Prot. n.17963 (25 March 2020). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesScRNA-seq data generated in this study are deposited in the Gene Expression Omnibus (GEO) under the accession number GSE168098.